1. Home
  2. Analysis
  3. Cardizem-cd
  4. Ibrance

Cardizem cd and Ibrance drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cardizem cd (diltiazem hydrochloride) and Ibrance (palbociclib). Common drug interactions include fatigue among females.

The phase IV clinical study analyzes what interactions people have when they take Cardizem cd and Ibrance. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Cardizem cd?

Cardizem cd has active ingredients of diltiazem hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 6,045 Cardizem cd users. Check the latest studies of Cardizem cd.

What is Ibrance?

Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,434 Ibrance users. Check the latest studies of Ibrance.

On Aug, 09, 2026

15 people who take Cardizem cd and Ibrance together, and have interactions are studied.

Cardizem cd and Ibrance drug interactions.

What are the common drug interactions of Cardizem Cd and Ibrance, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. White blood cell count decreased
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Pleural effusion (water on the lungs)
  5. Meningioma (a diverse set of tumours arising from the meninges)
  6. Nausea (feeling of having an urge to vomit)
  7. Constipation
  8. Diarrhoea
  9. Hypersomnia (excessive daytime sleepiness (eds))
  10. Nerve compression

male:

n/a

What are the common drug interactions of Cardizem Cd and Ibrance, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Fatigue (feeling of tiredness)
  2. White blood cell count decreased
  3. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  4. Pleural effusion (water on the lungs)
  5. Meningioma (a diverse set of tumours arising from the meninges)
  6. Constipation
  7. Diarrhoea
  8. Hypersomnia (excessive daytime sleepiness (eds))
  9. Nerve compression
  10. Pain

What are the existing conditions these people have? *

  1. Neoplasm Malignant (cancer tumour): 3 people, 20.00%
  2. Breast Cancer Female: 3 people, 20.00%
  3. Stress And Anxiety: 2 people, 13.33%
  4. Blood Pressure Abnormal: 2 people, 13.33%
  5. Bone Density Abnormal: 2 people, 13.33%
  6. Bone Density Increased: 2 people, 13.33%
  7. Breast Cancer: 2 people, 13.33%
  8. Breast Cancer Metastatic: 2 people, 13.33%
  9. Breast Cancer Stage Iv: 2 people, 13.33%
  10. Cardiac Disorder: 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Cardizem cd and Ibrance?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cardizem cd and Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cardizem cd:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ibrance:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cardizem cd and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ibrance and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on diltiazem hydrochloride and palbociclib (the active ingredients of Cardizem cd and Ibrance, respectively), and Cardizem cd and Ibrance (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.